Surgical Resection Versus Transarterial Chemoembolization for Intermediate Stage Hepatocellular Carcinoma (BCLC-B): An Unsolved Question.

Details

Serval ID
serval:BIB_1275C0764544
Type
Article: article from journal or magazin.
Publication sub-type
Letter (letter): Communication to the publisher.
Collection
Publications
Institution
Title
Surgical Resection Versus Transarterial Chemoembolization for Intermediate Stage Hepatocellular Carcinoma (BCLC-B): An Unsolved Question.
Journal
Hepatology
Author(s)
Labgaa I., Demartines N., Melloul E.
ISSN
1527-3350 (Electronic)
ISSN-L
0270-9139
Publication state
Published
Issued date
02/2019
Peer-reviewed
Oui
Volume
69
Number
2
Pages
923
Language
english
Notes
Publication types: Letter ; Comment
Publication Status: ppublish
Abstract
We have read the article of Hyun MH et al. with great interest (1). We commend the authors for this study that tackles a crucial point in the treatment of hepatocellular carcinoma (HCC). There is a critical need to refine and eventually to expand the selection criteria of HCC patients who may benefit from curative therapies such as surgical resection (SR). There is accumulating evidence on improved survival after SR as opposed to transarterial chemoembolization (TACE) in patients with intermediate stage HCC (Barcelona Clinic Liver Cancer Stage B (BCLC-B)), although American (AASLD) and European (EASL) consensus guidelines recommend TACE in this setting (2, 3). This article is protected by copyright. All rights reserved.
Keywords
Carcinoma, Hepatocellular/surgery, Chemoembolization, Therapeutic, Hepatectomy, Humans, Liver Neoplasms/surgery
Pubmed
Web of science
Open Access
Yes
Create date
07/11/2018 12:05
Last modification date
26/06/2020 5:21
Usage data